We initiate coverage on Rocket Lab with a Strong Sell rating and a $36.00 target. Neutron's launch delay into 2027, dilutive Iridium financing, and gross margin compression make the stock's 28 times sales multiple unsustainable.
Key points
- $37.0 billion enterprise value discounts flawless execution across both medium-lift launch and constellation manufacturing while operating cash burn continues.
- 2027 delay for the inaugural Neutron launch pushes medium-lift commercial revenue realization back by at least a year and extends vehicle development spending.
- $2.86 billion cash outlay and 42.4 million shares of dilution from the pending Iridium acquisition fundamentally alter capital structure and capital intensity.
The call
The market is far too optimistic on launch economics and timing. At $55.25, Rocket Lab trades at 28 times estimated fiscal 2026 revenue of $977 million and 94 times pro forma combined operating profit. This valuation requires Neutron to capture commercial medium-lift share immediately without technical setbacks, while satellite manufacturing maintains software-like multiples despite fixed-price government procurement structures.
Quarterly Revenue, Gross Profit, and Operating Loss ($M)- Revenue
- Gross profit
- Operating loss
SEC XBRL data through Q2 FY26; desk forecasts Q3 FY26E to Q4 FY27E. As of October 15, 2026.
We initiate coverage with a Strong Sell rating and a $36.00 price target. Composite manufacturing flaws on Neutron's forward dome push the test flight into 2027, prolonging high research outlays. While Space Systems backlog conversion remains strong, gross margins are guided down to 30% in the third quarter. Dilution from 29.3 million ATM shares and collar-floor equity issuance for Iridium dilutes per-share compounding.
Bridge from Current Price to 12-Month Target ($ per share)Per-share walk from standalone valuation and Iridium accretion to target price. Desk estimates.
Valuation
| Valuation metric | Estimate |
|---|
| Fiscal 2027 standalone revenue | $1,310 million |
| Standalone EV / Sales target multiple | 14.0 times |
| Standalone enterprise value | $18,340 million |
| Iridium enterprise value contribution (11.0x EBITDA) | $5,280 million |
| Pro forma combined net debt | $610 million |
| Diluted pro forma shares outstanding | 711.1 million |
| 12-month target price | $36.00 |
We value standalone Rocket Lab at 14 times fiscal 2027 sales, supported by $4.1 billion in net liquidity. Combining Iridium adds $5.3 billion of value against $610 million of net debt post-closing. Downside asymmetry of 35% justifies a Strong Sell.
Risks
- Rapid resolution of composite tooling allows Neutron pad delivery ahead of revised schedules, accelerating heavy launch backlog conversion.
- Federal government constellation awards expand beyond the $981 million NITE-STAR ceiling, driving faster Space Systems billings.
- Unanticipated termination of the Iridium merger preserves Rocket Lab's cash hoard without adding $1.78 billion of debt.
What would change my mind
A confirmed, flawless hot-fire and successful orbital demonstration flight of Neutron in early 2027 alongside sustained Space Systems operating profit would force a rating upgrade.